Immuneering (IMRX) Change in Account Payables (2020 - 2026)
Immuneering's (IMRX) quarterly Change in Account Payables came in at -$89579.0 in Q1 2026, up 86.98% year-on-year from -$47909.0 in Q1 2025, and down 222.02% quarter-over-quarter from $73415.0 in Q4 2025.
Immuneering (IMRX) Change in Account Payables (2020 - 2026) Analysis & Trends
Immuneering's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$89579.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 86.98% year-over-year to -$89579.0 in Q1 2026; TTM through Mar 2026 was $197493.0, a 121.53% increase from a year earlier, with the FY2025 full-year figure at -$400799.0, down 257.4% from the prior year.
- Change in Account Payables slipped to -$89579.0 in Q1 2026 per IMRX's latest filing, from $73415.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.2 million in Q2 2025 and bottomed at -$974893.0 in Q3 2025.
- The 5-year median for Change in Account Payables is $56741.0 (2024), against an average of $2988.2.
- Across the five-year window, Change in Account Payables tumbled 731.07% in 2022 and jumped 675.42% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $816177.0 in 2022, then slumped by 79.1% to $170568.0 in 2023, then sank by 66.73% to $56741.0 in 2024, then gained by 29.39% to $73415.0 in 2025, then plunged by 222.02% to -$89579.0 in 2026.
- Per Business Quant, the three latest IMRX Change in Account Payables figures stand at -$89579.0 (Q1 2026), $73415.0 (Q4 2025), and -$974893.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Immuneering | 283.85 Mn | 283.85 Mn | - | -89,579.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,579.00 |
| Mar 31, 2026 | -89,579.00 |
| Dec 31, 2025 | 73,415.00 |
| Dec 31, 2025 | 73,415.00 |
| Sep 30, 2025 | -974,893.00 |
| Sep 30, 2025 | -974,893.00 |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | -687,871.00 |
| Mar 31, 2025 | -687,871.00 |
| Dec 31, 2024 | 56,741.00 |
| Dec 31, 2024 | 56,741.00 |
| Sep 30, 2024 | -679,454.00 |
| Sep 30, 2024 | -679,454.00 |
| Jun 30, 2024 | 393,177.00 |
| Jun 30, 2024 | 393,177.00 |
| Mar 31, 2024 | 117,393.00 |
| Mar 31, 2024 | 117,393.00 |
| Dec 31, 2023 | 170,568.00 |
| Dec 31, 2023 | 170,568.00 |